T
Tsai Wang Chang
Researcher at National Cheng Kung University
Publications - 2
Citations - 1259
Tsai Wang Chang is an academic researcher from National Cheng Kung University. The author has contributed to research in topics: Lapatinib & Neoadjuvant therapy. The author has an hindex of 2, co-authored 2 publications receiving 1129 citations.
Papers
More filters
Journal ArticleDOI
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
José Baselga,José Baselga,Ian Bradbury,Holger Eidtmann,Serena Di Cosimo,Serena Di Cosimo,Evandro de Azambuja,Claudia Aura,Henry L. Gomez,Phuong Dinh,Karine Fauria,Veerle Van Dooren,Gursel Aktan,Aron Goldhirsch,Tsai Wang Chang,Zsolt Horváth,Maria Antonia Coccia-Portugal,Julien Domont,Ling Min Tseng,Georg Kunz,Joohyuk Sohn,Vladimir Semiglazov,Guillermo Lerzo,Marketa Palacova,Volodymyr Probachai,Lajos Pusztai,Michael Untch,Richard D. Gelber,Martine Piccart-Gebhart +28 more
TL;DR: Dual inhibition of Her2 might be a valid approach to treatment of HER2-positive breast cancer in the neoadjuvant setting, and the two anti-HER2 agents given together would be better than single-agent therapy.
Journal ArticleDOI
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
Debora Fumagalli,David Venet,Michail Ignatiadis,Hatem A. Azim,Marion Maetens,Françoise Rothé,Roberto Salgado,Ian Bradbury,Lajos Pusztai,Nadia Harbeck,Henry L. Gomez,Tsai Wang Chang,Maria Antonia Coccia-Portugal,Serena Di Cosimo,Evandro de Azambuja,Lorena de la Peña,Paolo Nuciforo,Jan C. Brase,Jens Huober,José Baselga,Martine Piccart,Sherene Loi,Christos Sotiriou +22 more
TL;DR: The expression of ERBB2/HER2 was the most significant predictor of pCR, followed by HER2-enriched subtype, ESR1, treatment arm, ER immunohistochemical analysis scores, Genomic Grade Index, immune, proliferation, and AKT/mTOR GSs.